STAT+: Obesity drug from Viking Therapeutics hits target in Phase 2 study, raising hopes for a competitor to existing medicines

An obesity drug from Viking Therapeutics succeeded in a Phase 2 study, helping patients lose nearly 15% of weight and further fueling the competition in the obesity market. 
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks